Juan Turnes
Overview
Explore the profile of Juan Turnes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turnes J, Garcia-Herola A, Morillo-Verdugo R, Mendez M, Hernandez C, Sicras-Mainar A
Rev Esp Sanid Penit
. 2025 Feb;
26(3):98-112.
PMID: 39927807
Objectives: Direct-acting antivirals (DAAs) share pharmacokinetic pathways with many comedications commonly administered to patients living with chronic hepatitis C virus (HCV) infection (PLWHCV). International guidelines recommend a thorough drug-drug interaction...
2.
Matute-Gonzalez M, Darnell A, Comas-Cufi M, Pazo J, Soler A, Saborido B, et al.
Insights Imaging
. 2024 Nov;
15(1):280.
PMID: 39576290
Objective: To develop a domain-specific large language model (LLM) for LI-RADS v2018 categorization of hepatic observations based on free-text descriptions extracted from MRI reports. Material And Methods: This retrospective study...
3.
Parada Vazquez P, Perez-Cachafeiro S, Castineira Dominguez B, Gonzalez-Perez J, Mera Calvino J, Souto-Rodriguez R, et al.
Gastroenterol Hepatol
. 2024 Jul;
48(1):502226.
PMID: 38950646
Objective: Direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection offer an opportunity to eliminate the disease. This study aimed to identify and relink to care HCV patients previously...
4.
Diaz-Gonzalez A, Forner A, Turnes J
Liver Int
. 2024 Jun;
44(7):1575-1577.
PMID: 38886910
No abstract available.
5.
Ruiz-Cobo J, Llaneras J, Forns X, Gallego Moya A, Conde Amiel I, Arencibia A, et al.
Aliment Pharmacol Ther
. 2024 May;
60(2):201-211.
PMID: 38695095
Background: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of...
6.
Ampuero J, Aller R, Gallego-Duran R, Crespo J, Calleja J, Garcia-Monzon C, et al.
J Gastroenterol
. 2024 Apr;
59(7):586-597.
PMID: 38619600
Background: MASLD can manifest as hepatocellular damage, which can result in mild elevation of aminotransferases. However, in some patients, MASLD presents with cholestatic pattern. Objective: To assess the impact of...
7.
Marti-Aguado D, Pazo J, Diaz-Gonzalez A, de Las Heras Paez de la Cadena B, Conthe A, Gallego Duran R, et al.
Gastroenterol Hepatol
. 2024 Apr;
47(6):646-648.
PMID: 38582150
No abstract available.
8.
Aller R, Calleja J, Crespo J, Romero-Gomez M, Turnes J, Benmarzouk-Hidalgo O, et al.
Gastroenterol Hepatol
. 2023 Jun;
47(4):337-346.
PMID: 37343722
Objective: To describe in detail the epidemiology, diagnosis, clinical management, treatment options, impact on quality of life and unmet needs of patients with advanced liver fibrosis (F3-F4) associated with non-alcoholic...
9.
Calleja J, Delgado Sanchez O, Fuentes Pradera M, Llop E, Lopez Zarraga F, Lozano M, et al.
Gastroenterol Hepatol
. 2023 Apr;
47(1):32-50.
PMID: 37028757
Objective: The lack of consensus and specific guidelines, and the introduction of new treatments in thrombocytopenia management in liver cirrhosis patients, required a series of recommendations by experts to improve...
10.
Lazarus J, Villota-Rivas M, Jimenez-Gonzalez C, Santos-Laso A, Iruzubieta P, Arias-Loste M, et al.
Clin Liver Dis
. 2023 Apr;
27(2):515-533.
PMID: 37024221
Globally, the use of digital health interventions (DHIs) is expanding, along with growing scientific evidence of their effectiveness. Given the high and increasing prevalence of noncommunicable liver disease, we surveyed...